

Indice

1. Introducción.....	3
1.1 Cáncer	3
1.1.1 Regulación en cáncer.....	6
1.1.1.1 Factores de transcripción	7
1.1.1.2 Rutas de señalización.....	9
1.1.2 Características comunes en cáncer	12
1.1.3 Heterogeneidad en cáncer.....	18
1.1.4 Tratamientos en cáncer.....	21
1.1.4.1 Tratamientos dirigidos y medicina personalizada de precisión .	23
1.2 Técnicas ómicas en cáncer	28
1.2.1 Transcriptómica en cáncer.....	29
1.2.2 Single cell	31
1.2.3 Técnicas de análisis de transcriptomas: GSEA y modelos mecanísticos	32
2. Objetivos y estructura de la tesis	37
3. The pan-cancer pathological regulatory landscape	43
3.1 Abstract	43
3.2 Introduction	44
3.3 Results and discussion.....	46
3.3.1 Changes in TF activity across the different cancers.....	46
3.3.2 Changes in TF activity across cancer stages	52
3.3.3 TF activity and survival.....	52
3.3.4 Combined contribution of TF activity to survival and the impact of tumour purity.....	57
3.3.4 Potential limitations of the method	61

3.4 Conclusions	63
3.5 Methods	64
3.5.1 Cancer samples used.....	64
3.5.2 Gene expression data processing	64
3.5.3 Transcription factors used in the study	65
3.5.4 Estimation of significant transcription factor activities in a cancer datasets	66
3.5.5 Estimation of personalized transcription factor activities per individual.....	68
3.5.6 Correlation between transcription factor activity and patient survival	70
3.5.7 Tumour purity estimation	70
3.5.8 Code availability	71
3.5.9 Supplementary data	71
3.6 References	71
4. Mechanistic models of signaling pathways deconvolute the glioblastoma single-cell functional landscape.....	83
4.1 Abstract.....	83
4.2 Introduction	84
4.2 Materials and methods.....	86
4.2.1 Data.....	86
4.2.2 Data imputation and primary processing	87
4.2.3 Hipathia mechanistic model	87
4.2.4 Differential signalling activity	88
4.2.5 Signaling circuits associated with cancer hallmarks.....	88
4.2.6 Subtyping of cancer cells.....	89
4.2.7 Supplementary data	89
4.3 Results	89

4.3.1 Selection of the optimal imputation method	89
4.3.2 Functional characterization of cancer cells	93
4.3.3 Function-based stratification of glioblastoma cells	96
4.3.4 Effect of a drug at single-cell level	97
4.4 Discussion	103
4.5 Conclusions	107
4.6 References	108
5. Discusión general	121
5.1 Caracterización del estado de activación de elementos reguladores	121
5.2 Heterogeneidad regulatoria en cáncer	127
5.3 Heterogeneidad y medicina personalizada	133
6. Conclusiones generales	143
Referencias	145

Índice de figuras

Figura 1.1 Incidencia y mortalidad de cáncer por sexo y órgano..	4
Figura 1.2 <i>Hallmarks of cancer</i>	12
Figura 1.3 Eficacia de los 10 medicamentos más prescritos en EEUU sobre la población general	25
Figura 1.4 Auge de las ómicas	28
Figure 3.1 Change of TF activity in the different cancers studied	51
Figure 3.2 Change of activity in all TF included in this study across cancer stages in the different cancers studied.	53
Figure 3.3 K-M plots representing TF activities significantly associated to patient survival in all the cancers analysed	58
Figure 3.4 K-M plots representing TF activities significantly associated to patient survival	60
Figure 3.5 Combinations of TFs significantly associated to patient survival in the different cancers when a Cox model is applied	62
Figure 3.6 Schema of the TFTEA method to obtain TFs differentially activated between two conditions compared	67
Figure 3.7 Schema of the TFTEA method to obtain personalized values of survival	69
Figure 4.1 Clustering of the samples based on gene expression and signaling circuit activities obtained with different gene imputation methods	90
Figure 4.2 Circuits related to cancer hallmarks observed in the three neoplastic cell clusters.	92